# SUNRAY-02 (NCT06890598)

> Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: olomorasib plus pembrolizumab; olomorasib plus durvalumab
- Indication: stage II-III KRAS G12C-mutant non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06890598
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Olomorasib; Pembrolizumab; Durvalumab; Placebo
- Enrollment: 700
- Primary outcome: Part A: Disease-Free Survival (DFS) by Investigator Assessment
- Primary outcome: Part B: Progression-Free Survival (PFS) by BICR

## Indexed commentary on SUNRAY-02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sunray-02-nct06890598